Remove
Pages,Columns,Lines where

U.S. Pieter and Tableman (1997) (1997

	/ ppiloauoii i tuiliboi				
	Filing Date		2006-08-31		
INFORMATION DISCLOSURE	First Named Inventor Peter		er A. Stegmaier		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit				
(Not for Submission under 57 57 ft 1.55)	Examiner Name				
	Attorney Docket Numb	er	16455.12		

U.S.PATENTS

Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Patentee or Applicant of cited Document		ges,Columns,Lines where elevant Passages or Releva gures Appear	
1	4414661		1983-11-08	Karlstrom				
2	5850341		1998-12-15	Fournier et al	ı			
3	6084870		2000-07-04	Wooten et al				
4	6611755	B1	2003-08-26	Coffee et al				
h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add	
		U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove	
Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		int Passages or R	
1								
h to a	d additional U.S. Public	shed Ap	plication cital	ion information	please click the Ad	d button	Add	
			FOREIGN P	ATENT DOCUM	MENTS		Remove	
Cite No	Foreign Document Number ³					e or	vhere Relevant	TS
	1 2 3 4 4 h to acc	No Patent Number	No Patent Number Code1	No Patent Number Code Issue Date	No	No	Patent Number Code Issue Date Number Code Issue Date Number Code Issue Date Number Code Issue Date Code Issue Date Number Code Issue Date Number Code Issue Date Number Code Issue Date Number Number Number Code Issue Date Number Num	Patent Number No.

			Application Number							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Filing Date				2006-08-31				
		First Named Inventor Peter			Peter	A. Stegmaier				
		Art Unit								
		Examiner Name								
			Attorney Docket Number			er	16455.12			
	1									
If you wis	h to a	dd additional Foreign P	atent Doo	cument	citation	informatio	n plea	ase click the Add buttor	Add	
			NON	-PATE	NT LITE	RATURE	DOC	UMENTS	Remove	
										$\overline{}$

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iten Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), T6 Initials* No publisher, city and/or country where published. Yakoh, T. et al.: "MACS: An Efficient Multicast Mechanism for Radiopacket Communication Among Multiple Mobile Robots Communications Computers and Signal Processing, 1993, IEEE Pacific Rim Conference, IEEE vol. 2, 19 May 1993

If you wish to add additional non-patent literature document citation information please click the Add button Add

EYAMINED SIGNATURE Date Considered Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reion of the Emperor must precede the senal number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Application Number Filing Date 2006-08-31 First Number Information DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1-99) First Number Information Pattern Variable Statement Information Inform

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97	and 1.98 to make	the appropriate selection(s):	
---------------	------------	------------------	-------------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- __ ☑ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David A. Jones/Reg. # 50,004	Date (YYYY-MM-DD)	2006-09-01					
Name/Print	David A. Jones	Registration Number	50004					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet for disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via fifed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.